Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of narcolepsy~* Good general health~* Willing and able to comply with the study design and schedule and other requirements~Exclusion Criteria:~* If female, pregnant or lactating~* Customary bedtime later than midnight~* History of significant medical condition, behavioral, or psychiatric disorder (including suicidal ideation), or surgical history~* Any other clinically relevant medical, behavioral or psychiatric disorder other than narcolepsy that is associated with excessive sleepiness~* History of significant cardiovascular disease~* Body mass index \> 34~* Excessive caffeine use - \> 600 mg/day of caffeine or \> 6 cups of coffee/day~* History of alcohol or drug abuse within the past 2 years~* Nicotine dependence that has an effect on sleep

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ADX-N05 (Type: EXPERIMENTAL): ADX-N05 to be taken once a day for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match ADX-N05 to be taken once a day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).